FrancophonIA/ELRC3.0 huggingface dataset:
English: If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Teva Pharma B.V. once at the start of treatment.
Maltese: Jekk kellek uġigħ sever f'sidrek (anġina mhux stabbli' jew attakk tal-qalb) it-tabib tiegħek jista' jagħtik 300 mg ta' Clopidogrel Teva Pharma B.V. darba fil-bidu tat-trattament.
English: In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery.
Maltese: F'CURE, ma kienx hemm eċċessi ta' emorraġiji maġġuri b'clopidogrel miżjud ma' ASA fis-7 ijiem wara operazzjoni ta' trapjant ta' bajpass koronarju f'pazjenti li waqqfu t-terapija aktar minn 5 ijiem qabel l-intervent kirurġiku.
English: After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Maltese: Wara dożi ripetuti ta' 75 mg clopidogrel kuljum,f'individwi b'mard tal-kliewi sever (tneħħija tal-kreatinina minn 5 sa 15 ml/min) l-inibizzjoni għall-aggregazzjoni ta' plejtlets indott mill-ADP kien aktar baxx (25 %) minn dak osservat f'individwi b'saħħithom, madanakollu, it-titwil fiż-żmien ta' ħin ta' emorraġiji kien simili għal dak osservat f'individwi b'saħħithom li kienu qed jirċievu 75 mg clopidogrel kuljum..
English: As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs).
Maltese: Bħal fil-każ ta' sustanzi oħra kontra lplejtlets, clopidrogrel għandu jintuża b'kawtela f'pazjenti li jista' jkollhom riskju ta' iktar dmija minn trawma, interventi kirurġiċi jew kundizzjonijiet patoloġiċi oħra u pazjenti li jkunu qed jirċievu l-kura b'ASA, heparin, inibituri ta' glycoprotein IIb/IIIa jew mediċini kontra l-infjammazzjoni li m'humiex sterojdi (NSAIDs) li jinkludu l-inibituri ta' Cox-2, jew inibituri selettivi tal-ġbir mill-ġdid ta' serotonin (SSRIs).
English: Taste disturbances
Maltese: Bijotrasformazzjoni
English: Other medicines and Clopidogrel Teva Pharma B.V.
Maltese: Mediċini oħra u Clopidogrel Teva Pharma B.V.
English: Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8).
Maltese: Minħabba r-riskju ta' reazzjonijiet emorraġiji avversi u effetti ematoloġiċi, l-għadd ta' ċelluli taddemm u/jew kull ittestjar ieħor xieraq għandhom jiġu kkonsidrati waqt it-trattament kull meta jkun hemm sintomi kliniċi li jindikaw emorraġiji (ara sezzjoni 4.8).
English: Light pink to pink, capsule-shaped film-coated tablets debossed with “C75” on one side and plain on the other side.
Maltese: Pilloli miksija b'rita li huma ta' lewn roża ċar għal roża, f'għamla ta' kapsuli b' “C75” imnaqqxa fuq naħa waħda mingħajr tinqix fuq in-naħa l-oħra.
English: • You should also tell your doctor immediately if you develop a medical condition (known as Thrombotic Thrombocytopenic Purpura) that includes altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas) (see section 4 ‘Possible Side Effects')
Maltese: • Għandek tgħarraf lit-tabib tiegħek minnufih jekk tiżviluppa kundizzjoni medika (magħrufa bħala Purpura Tromboċitopenika Trombotika) li tinkludi tibdil fl-imġieba tiegħek, uġigħ ta' ras, koma, disturbi fil-vista, attakki pupletiċi (attakki tal-qamar), indeboliment tal-kliewi, deni, għeja kbira ħafna, debulezza jew fsada fl-istonku, l-imsaren jew il-ġilda ( li jinkludu dbabar żgħar ħomorjew żoni bi tbenġil kbir) (ara s-sezzjoni 4 ‘Effetti sekondarji possibbli')
English: • a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression,
Maltese: • inibitur selettiv tal-ġbir mill-ġdid ta' serotonin (li jinkludi iżda mhux limitat għal fluoxetine jew fluvoxamine), mediċini li ssoltu jintużaw fil-kura tad-dipressjoni,
English: If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable, clopidogrel should be discontinued 7 days prior to surgery.
Maltese: Jekk pazjent jagħżel li jkollu operazzjoni u l-effett kontra l-plejtlets huwa temporanjament mhux mixtieq, clopidrogrel għandu jitwaqqaf 7 ijiem qabel il-kirurġija.
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel
Maltese: Informazzjoni għall-utent Clopidogrel Teva Pharma B.V. 75 mg pilloli miksija b'rita clopidogrel
English: Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel
Maltese: U MNEJN GĦANDU JINGĦATA Clopidogrel Teva Pharma B.V. 75 mg pilloli miksija b'rita clopidogrel użu orali
English: E.g. abciximab,
Maltese: • Emorraġija ġol-addome
English: In a dose escalation study of 86 neonates or infants up to 24 months of age at risk for thrombosis (PICOLO), clopidogrel was evaluated at consecutive doses of 0.01, 0.1 and 0.2 mg/kg in neonates and infants and 0.15 mg/kg only in neonates.
Maltese: Fi studju b'dożi li jibqgħu jogħlew u li sar f'86 tarbija tat-twelid jew tfal ċkejknin sa 24 xahar ta' età f'riskju ta' trombożi (PICOLO), clopidogrel ġie evalwat f'dożi konsekuttivi ta' 0.01, 0.1 u 0.2 mg/kg fit-trabi tat-twelid u fit-tfal ċkejknin u 0.15 mg/kg fit-trabi tat-twelid biss.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON of peelable blisters (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet)
Maltese: TAGĦRIF LI GĦANDU JIDHER FUQ IL-PAKKETT TA' BARRA KARTUNA TA' BARRA għal folji li jitqaxxru (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 jew 100x1 pillola miksija b'rita)
English: Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure.
Maltese: Purpura Tromboċitopenika Trombotika (Thrombotic Thrombocytopenic Purpura -TTP) Ġiet rapportata Purpura Tromboċitopenika Trombotika (TTP) b'mod rari ħafna wara l-użu ta' clopidrogrel, xi kultant wara espożizzjoni qasira.
English: Thrombotic Thrombocytopenic Purpura (TTP)
Maltese: • Pjan tal-immaniġġar tar-riskju (RMP) Mhux applikabbli.
English: • Glycoprotein IIb/IIIa inhibitors (medicines used to stop blood clotting).
Maltese: • Impedituri ta' glycoprotein IIb/IIIa (mediċini li jintużaw biex iwaqqfu d-demm milli jgħaqqad). eż. abciximab, eptifibatide jew tirofiban.
English: Esomeprazole is expected to give a similar interaction with clopidogrel.
Maltese: Esomeprazole hu mistenni li jipproduċi interazzjoni bħal din ma' clopidogrel.
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets
Maltese: IL-PRODOTT MEDIĊINALI Clopidogrel Teva Pharma B.V.75 mg pilloli miksija b'rita
English: In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Maltese: Fl-analiżi tal-intenzjoni tal-kura, ġew osservati 939 każ fil-grupp ta' clopidogrel u 1,020 każ ma' ASA (tnaqqis tar-riskju relattiv, relative risk reduction (RRR)) 8.7 %, [95 % CI: 0.2 sa 16.4]; p = 0.
English: Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel.
Maltese: Tagħrif mill-istudju CAPRIE jindika li phenytoin u tolbutamide li jiġu mmetabolizzati minn CYP2C9 jistgħu jiġu amminsitrati flimkien ma' clopidogrel b'mod sikur.
English: Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (seesection 5.1).
Maltese: Tagħrif minn prova klinika tappoġġa l-użu sa 12-il xahar, u l-aħjar benefiċċju ġie osservat fi żmien 3 xhur (ara sezzjoni 5.1).
English: What Clopidogrel Teva Pharma B.V. is and what it is used for What you need to know before you take Clopidogrel Teva Pharma B.V. How to take Clopidogrel Teva Pharma B.V.
Maltese: Clopidogrel Teva Pharma B.V. ma' ikel u xorb Tista' tieħu Clopidogrel Teva Pharma B.V mal-ikel jew fuq stonku vojt.
English: Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk.
Maltese: Dan il-prodott mediċinali fih hydrogenated castor oil li jista' jikkaġuna dardir fl-istonku u dijarea.
English: An overdose is likely to cause an increased risk of bleeding.
Maltese: Doża eċċessiva x'aktarx tikkawża riskju ogħla ta' emorraġija.
English: A serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body).
Maltese: • Kundizzjoni serja li tissejjaħ purpura trombolitika trombotika (distub rari tas-sistema li biha jgħaqqad id-demm li tikkaġuna emboli multipli tad-demm jifformaw madwar il-ġisem).
English: No clinically significant pharmacodynamic interactions were observed when clopidogrel was co administered with atenolol, nifedipine, or both atenolol and nifedipine.
Maltese: Ma ġewx osservati interazzjonijiet farmakodinamiċi li kienu klinikament sinifikanti meta colpidogrel ingħata flimkien ma' atenolol u nifedipine,.
English: Further information on RoActemra can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/RoActemra.
Maltese: ema.europa.eu/medicines/human/EPAR/RoActemra.
English: Other information about RoActemra:
Maltese: Informazzjoni oħra dwar RoActemra:
English: Out of 51 patients who had CRS after being given the CAR-T cell medicine tisagenlecleucel, 39 responded to treatment with RoActemra (76.5%), while 8 out 15 patients (53.3%) who had CRS after being given axicabtagene ciloleucel responded.
Maltese: Minn 51 pazjent li kellhom CRS wara li ngħataw il-mediċina taċ-ċellola CAR-T tisagenlecleucel, 39 irrispondew għallkura b'RoActemra (76.5 %), filwaqt li 8 minn 15-il pazjent (53.3 %) li kellhom CRS wara li ngħataw axicabtagene ciloleucel irrispondew għall-kura.
English: RoActemra received a marketing authorisation valid throughout the EU on 16 January 2009.
Maltese: RoActemra ngħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fis-16 ta' Jannar 2009.
English: RoActemra contains the active substance tocilizumab.
Maltese: RoActemra fih is-sustanza attiva tokiliżumab.
English: In severe rheumatoid arthritis not previously treated with methotrexate, RoActemra given by infusion was investigated in one main study involving 1,162 patients.
Maltese: F'artrite rewmatojde severa li ma ġietx ikkurata preċedentement b'metotressat, RoActemra mogħti b'infużjoni ġie investigat fi studju ewlieni wieħed li involva 1,162 pazjent.
English: After 6 months of treatment, 45% of patients taking RoActemra in combination with methotrexate (130 out of 290) and 39% of patients taking RoActemra on its own (113 out of 292) achieved remission (did not show symptoms of the disease), compared with 15% of those taking placebo plus methotrexate (43 out of 287).
Maltese: Wara 6 xhur ta' kura, 45 % tal-pazjenti li kienu qed jieħdu RoActemra flimkien ma' metotressat (130 minn 290) u 39 % tal-pazjenti li kienu qed jieħdu RoActemra waħdu (113 minn 292) kisbu remissjoni (ma wrewx sintomi tal-marda), meta mqabbla ma' 15 % ta' dawk li kienu qed jieħdu l-plaċebo flimkien ma' metotressat (43 minn 287).
English: Cytokine release syndrome (CRS)
Maltese: Sindromu tar-rilaxx taċ-ċitokina (CRS)
English: After 4 to 6 months of treatment, 26% of patients on RoActemra (21 out of 82) had a flare-up of symptoms during treatment, compared with 48% of patients taking placebo (39 out of 81).
Maltese: Wara 4 xhur sa 6 xhur ta' kura, 26 % tal-pazjenti fuq RoActemra (21 minn 82) feġġewlhom is-sintomi f'daqqa matul il-kura, meta mqabbla ma' 48 % tal-pazjenti li ngħataw il-plaċebo (39 minn 81).
English: Juvenile idiopathic polyarthritis
Maltese: Poliartrite idjopatika ġuvenili
English: In this study 85% (64 out of 75) patients treated with RoActemra responded to treatment and no longer had fever after 3 months, compared with 24% (9 out of 37) patients receiving placebo.
Maltese: F'dan l-istudju 85 % (64 minn 75) tal-pazjenti kkurati b'RoActemra rrispondew għallkura u ma kellhomx iżjed deni wara 3 xhur, meta mqabbla ma' 24 % (9 minn 37) tal-pazjenti li ngħataw il-plaċebo.
English: In the fourth study, which included 498 patients who had an inadequate response to TNF blockers, patients receiving RoActemra with methotrexate were around 9 times more likely to respond than those receiving placebo with methotrexate.
Maltese: Fir-raba' studju, li inkluda 498 pazjent li kellhom rispons inadegwat għall-imblokkaturi tat-TNF, il-pazjenti li rċevew RoActemra ma' metotressat kellhom madwar 9 darbiet aktar probabbiltà li jirrispondu minn dawk li rċevew il-plaċebo ma' metotressat.
English: The most common side effects (occurring in up to 1 patient in 10) with RoActemra are upper respiratory tract infections (nose and throat infection), nasopharyngitis (inflammation of the nose and throat), headache, hypertension (high blood pressure) and abnormal liver function tests.
Maltese: L-effetti sekondarji l-aktar komuni (li dehru f'mhux aktar minn pazjent 1 minn kull 10) b'RoActemra huma infezzjonijiet fl-apparat respiratorju ta' fuq (infezzjoni fl-imnieħer u fil-gerżuma), nażofarinġite (infjammazzjoni tal-imnieħer u tal-gerżuma), uġigħ ta' ras, ipertensjoni (pressjoni tad-demm għolja) u testijiet tal-funzjoni tal-fwied anormali.
English: What are the risks associated with RoActemra?
Maltese: X'inhuma r-riskji assoċjati ma' RoActemra?
English: CRS is a side effect of certain cancer treatments and RoActemra is used for CRS caused by chimeric antigen receptors (CAR) T-cell medicines.
Maltese: CRS hija effett sekondarju ta' ċerti kuri tal-kanċer u RoActemra jintuża għal CRS ikkawżata minn mediċini taċ-ċellola-T tar-reċetturi tal-antiġen kimeriku (CAR, chimeric antigen receptors)
English: In the first study, RoActemra was more effective than placebo in treating rheumatoid arthritis: after 6 months of treatment with RoActemra, 61% of patients responded to treatment compared with 32% on placebo.
Maltese: Flewwel studju, RoActemra kien aktar effettiv mill-plaċebo fil-kura tal-artrite rewmatojde: wara 6 xhur ta' kura b'RoActemra, 61 % tal-pazjenti rrispondew għall-kura meta mqabbla ma' 32 % fuq il-plaċebo.
English: • adults with moderate to severe active rheumatoid arthritis whose previous treatments with disease modifying antirheumatic drugs (DMARDs), such as methotrexate or medicines known as tumour necrosis factor (TNF) blockers, have not worked well or were not tolerated;
Maltese: • adulti b'artrite rewmatojde attiva minn moderata għal severa li l-kuri preċedenti tagħhom b'mediċini antirewmatiċi li jimmodifikaw il-marda (DMARDs, disease modifying antirheumatic drugs), bħal metotressat jew mediċini magħrufa bħala imblokkaturi tal-fattur tan-nekrożi tumorali
English: RoActemra given by injection under the skin was investigated in two studies involving 1,918 patients with moderate to severe rheumatoid arthritis where previous treatment with DMARD had not worked well.
Maltese: RoActemra mogħti b'injezzjoni taħt il-ġilda ġie investigat f'żewġ studji li involvew 1,918-il pazjent b'artrite rewmatojde moderata sa severa fejn kura preċedenti b'DMARD ma kinitx ħadmet sew.
English: Tocilizumab attaches to the receptor for a messenger molecule or ‘cytokine' called interleukin-6.
Maltese: It-tokiliżumab teħel mar-riċettur għal molekula messaġġier jew “ċitokina” li tissejjaħ interleukin-6.
English: Studies show RoActemra is effective at reducing symptoms of several inflammatory conditions.
Maltese: L-istudji juru li RoActemra huwa effettiv biex inaqqas is-sintomi ta' diversi kondizzjonijiet infjammatorji.
English: How is RoActemra used?
Maltese: RoActemra?
English: As for all medicines, data on the use of RoActemra are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' RoActemra hija ssorveljata kontinwament.
English: This messenger is involved with inflammation and is found at high levels in patients with rheumatoid arthritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, giant cell arteritis and CRS.
Maltese: Dan il-messaġġier huwa involut fl-infjammazzjoni u jinstab f'livelli għoljin f'pazjenti bl-artrite rewmatojde, bl-artrite idjopatika ġuvenili sistemika, bil-poliartrite idjopatika ġuvenili u bl-arterite ta' ċellola ġganta u b'CRS.
English: In giant cell arteritis, RoActemra given by injection under the skin was found more effective than placebo in one main study involving 251 adults.
Maltese: Fl-arterite ta' ċellola ġganta, RoActemra mogħti b'injezzjoni taħt il-ġilda nstab li kien aktar effettiv millplaċebo fi studju ewlieni wieħed li involva 251 adult.
English: The most serious side effects are serious infections, complications of diverticulitis (a disease affecting the gut) and hypersensitivity (allergic) reactions.
Maltese: L-effetti sekondarji l-aktar serji huma infezzjonijiet serji, kumplikazzjonijiet fid-divertikulite (marda li taffettwa l-musrana) u reazzjonijiet ta' sensittività eċċessiva (allerġiċi).
English: In systemic juvenile idiopathic arthritis, RoActemra given by infusion was compared with placebo in one main study involving 112 children in whom treatment with NSAID and corticosteroids did not work well enough.
Maltese: Fl-artrite idjopatika ġuvenili sistemika, RoActemra mogħti b'infużjoni tqabbel mal-plaċebo fi studju ewlieni wieħed li involva 112-il tifel u tifla li fuqhom il-kura b'NSAID u bil-kortikosterojdi ma ħadmitx tajjeb biżżejjed.
English: One of the studies, which involved 1,196 patients, also showed that the combination of RoActemra and methotrexate slowed down the damage to the joints and improved physical function after up to 2 years, when compared with the combination of placebo and methotrexate.
Maltese: Wieħed mill-istudji, li involva 1,196 pazjent, wera wkoll li l-kombinazzjoni ta' RoActemra u metotressat naqqset ukoll il-ħsara fil-ġogi u tejbet il-funzjoni fiżika sa sentejn wara, meta mqabbla mal-kombinazzjoni tal-plaċebo u metotressat.
English: • adults with severe rheumatoid arthritis that is getting worse in patients who have not been previously treated with a medicine called methotrexate;
Maltese: • adulti b'artrite rewmatojde severa li tkun qed tmur għall-agħar f'pazjenti li ma ġewx ikkurati preċedentement b'mediċina li tissejjaħ metotressat;
English: Another study involving 51 children from 1 year of age showed that RoActemra given by injection under the skin had a similar distribution in the body and effect on the disease to that previously seen with RoActemra given by infusion.
Maltese: Studju ieħor li involva 51 tifel u tifla minn sena ‘l fuq wera li RoActemra mogħti b'injezzjoni taħt il-ġilda kellu distribuzzjoni fil-ġisem u effett fuq il-marda simili għal dawk li kienu jidhru b'RoActemra mogħti b'infużjoni.
English: In three of these studies, RoActemra was compared with placebo, as an add-on to failing treatment with conventional rheumatoid arthritis medicines in a total of over 3,000 patients.
Maltese: Fi tlieta minn dawn l-istudji, RoActemra tqabbel mal-plaċebo bħala żieda ma' kura li ma tkunx irnexxiet b'mediċini konvenzjonali għall-artrite rewmatojde f'total ta' iktar minn 3,000 pazjent.
English: For the treatment of moderate to severe rheumatoid arthritis where other medicines were unsuccessful, RoActemra given by infusion was studied in five main studies involving a total of over 4,000 adults.
Maltese: Għall-kura ta' artrite rewmatojde moderata sa severa fejn mediċini oħra ma kellhomx suċċess, RoActemra mogħti b'infużjoni ġie studjat f'ħames studji ewlenin li involvew total ta' aktar minn 4,000 adult.
English: The active substance in RoActemra, tocilizumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific target (called an antigen) in the body.
Maltese: Is-sustanza attiva f'RoActemra, it-tokiliżumab, hija antikorp monoklonali, tip ta' proteina li tfasslet sabiex tagħraf u teħel ma' struttura fil-mira speċifika (imsejħa antiġen) fil-ġisem.
English: The company that markets RoActemra must supply all doctors expected to prescribe the medicine with an educational pack containing important information on the safety and correct use of RoActemra.
Maltese: Il-kumpanija li tqiegħed RoActemra fis-suq għandha tagħti lit-tobba kollha li mistennija jippreskrivu lmediċina pakkett edukattiv b'informazzjoni importanti dwar is-sigurtà u l-użu korrett ta' RoActemra.
English: RoActemra (tocilizumab)
Maltese: RoActemra huwa mediċina li tintuża biex tikkura:
English: RoActemra given by infusion was considered to be effective at treating severe CRS based on a review of data from 66 patients who experienced this condition after they were given CAR-T cell medicines to treat a blood cancer.
Maltese: RoActemra mogħti b'infużjoni tqies li kien effettiv fil-kura ta' CRS sever abbażi ta' rieżami ta' data minn 66 pazjent li esperjenzaw din il-kondizzjoni wara li ngħataw mediċini taċ-ċellola CAR-T għall-kura ta' kanċer fid-demm.
English: Juvenile idiopathic arthritis
Maltese: Artrite idjopatika ġuvenili
English: RoActemra is also used to treat adults with giant cell arteritis, a disease in which arteries, usually of the head, are swollen.
Maltese: RoActemra jintuża wkoll biex jikkura adulti b'arterite ta' ċellola ġganta, marda li fiha l-arterji, normalment tar-ras, ikunu minfuħin.
English: One year after starting treatment, 56% of patients treated with RoActemra once a week did not have symptoms compared with 14% patients receiving placebo.
Maltese: Sena wara lbidu tal-kura, 56 % tal-pazjenti kkurati b'RoActemra darba fil-ġimgħa ma kellhomx sintomi meta mqabbla ma' 14 % tal-pazjenti li kienu qed jirċievu l-plaċebo.
English: The fifth study involving 673 patients showed that patients receiving RoActemra on its own were more likely to respond than those taking methotrexate on its own.
Maltese: Il-ħames studju li kien jinvolvi 673 pazjent wera li pazjenti li rċevew RoActemra waħdu kellhom aktar probabbiltà li jirrispondu minn dawk li kienu qed jieħdu metotressat waħdu.
English: In juvenile idiopathic polyarthritis, RoActemra given by infusion was compared with placebo in one main study involving 166 children from 2 years of age who could not take methotrexate or it did not work well enough.
Maltese: Fil-poliartrite idjopatika ġuvenili, RoActemra mogħti b'infużjoni tqabbel mal-plaċebo fi studju ewlieni wieħed li involva 166 tifel u tifla minn sentejn 'il fuq li ma setgħux jingħataw metotressat jew li fuqhom ma ħadimx tajjeb biżżejjed.
English: RoActemra can also be used in adults and children from 2 years of age for the treatment of severe or life-threatening cytokine release syndrome (CRS, a condition that can cause nausea, vomiting, pain and low blood pressure).
Maltese: RoActemra jista' jintuża wkoll f'adulti u fi tfal minn sentejn ‘il fuq għall-kura ta' sindromu tar-rilaxx taċċitokina sever jew ta' periklu għall-ħajja (CRS, kondizzjoni li tista' tikkawża nawżja, remettar, uġigħ u pressjoni tad-demm baxxa).
English: By preventing interleukin-6 attaching to its receptors, tocilizumab reduces the inflammation and other symptoms of these diseases.
Maltese: Billi tipprevjeni l-interleukin-6 milli teħel mar-riċetturi tagħha, it-tokiliżumab tnaqqas l-infjammazzjoni u sintomi oħra ta' dan il-mard.